TapewireFind a company

person · Reporting owner

SHARP PHILLIP A

Disclosed activity across 3 companies

Tapewire entity
83914
SEC CIK
0001226295

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132DirectorJanuary 23, 2025January 24, 2025
Syros Pharmaceuticals, Inc.SYRS · Entity 85437DirectorJune 01, 2022June 02, 2022
Vir Biotechnology, Inc.VIR · Entity 4522DirectorMay 22, 2023May 24, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date January 23, 2025 · Filed January 24, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2025-01-23 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2025-01-23 · Exercise / conversion · Acquired 11,250 · Balance 11,250

F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.

Row 2 · 2025-01-23 · Sale · Disposed 11,250 · Balance 0

F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.21 · Expires 2025-06-01Direct0 Reported balance After 2025-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-01-23 · Exercise / conversion · Disposed 11,250 · Balance 0

F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.

F3: This stock option was fully vested and exercisable as of June 1, 2016.

Common StockSEC Table I · non-derivativeIndirectby Trust266,899 Reported balance Holding disclosure · report date 2025-01-23 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 266,899

F2: Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.

Filing footnotes · ownership attribution and instrument terms

F1: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.

F2: Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.

F3: This stock option was fully vested and exercisable as of June 1, 2016.

Syros Pharmaceuticals, Inc.

Report date June 01, 2022 · Filed June 02, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2032-05-31Direct17,500 Reported balance After 2022-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-06-01 · Grant · Acquired 17,500 · Balance 17,500

F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Vir Biotechnology, Inc.

Report date May 22, 2023 · Filed May 24, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect121,174 Reported balance After 2023-05-22 transaction · row 1
1 source row

Row 1 · 2023-05-22 · Grant · Acquired 6,027 · Balance 121,174

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.74 · Expires 2033-05-21Direct12,054 Reported balance After 2023-05-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-05-22 · Grant · Acquired 12,054 · Balance 12,054

Common StockSEC Table I · non-derivativeIndirectSee footnote44,444 Reported balance Holding disclosure · report date 2023-05-22 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 44,444

F1: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee.

Common StockSEC Table I · non-derivativeIndirectSee footnote44,444 Reported balance Holding disclosure · report date 2023-05-22 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 44,444

F2: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee.

Common StockSEC Table I · non-derivativeIndirectSee footnote44,444 Reported balance Holding disclosure · report date 2023-05-22 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 44,444

F3: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee.

F2: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee.

F3: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 12, 2020 Filed Feb 13, 2020 21:06 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 30,000 $130.00 $3,900,000.00
Disclosure

SEC source: 0001735276-20-000016 · edgardoc.xml · nonDerivative · entry 3

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,633

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

Read SEC document
February 12, 2020 Filed Feb 13, 2020 21:06 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $9.14 $137,100.00
Disclosure

SEC source: 0001735276-20-000016 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

Read SEC document
February 12, 2020 Filed Feb 13, 2020 21:06 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $15.82 $237,300.00
Disclosure

SEC source: 0001735276-20-000016 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

Read SEC document
November 18, 2019 Filed Nov 20, 2019 21:17 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 15,000 $0.00 Strike: $16.43 $0.00
Disclosure

SEC source: 0001735276-19-000096 · edgardoc.xml · derivative · entry 6

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2019-12-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019.

Read SEC document
November 18, 2019 Filed Nov 20, 2019 21:17 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 810 $92.66 $75,054.60
Disclosure

SEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 4

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,633

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019.

F4 · price: Sale prices ranged from $92.53 to $92.74.

Read SEC document
November 18, 2019 Filed Nov 20, 2019 21:17 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 8,631 $91.97 $793,793.07
Disclosure

SEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 3

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,443

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019.

F3 · price: Sale prices ranged from $91.50 to $92.48.

Read SEC document
November 18, 2019 Filed Nov 20, 2019 21:17 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 5,559 $91.17 $506,814.03
Disclosure

SEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,074

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019.

F2 · price: Sale prices ranged from $90.50 to $91.49.

Read SEC document
November 18, 2019 Filed Nov 20, 2019 21:17 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $16.43 $246,450.00
Disclosure

SEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionSeries A-1 Convertible Preferred Stock · Derivative 44,444 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 8

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 44,444 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionSeries A-1 Convertible Preferred Stock · Derivative 44,444 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 7

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 44,444 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionSeries A-1 Convertible Preferred Stock · Derivative 44,444 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 6

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 44,444 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionSeries A-1 Convertible Preferred Stock · Derivative 88,888 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · derivative · entry 5

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 88,888 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionCommon Stock 44,444 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 4

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 44,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F4 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Christine Carey, over which the reporting person's spouse is co-trustee.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionCommon Stock 44,444 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 3

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 44,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Helena Sharp, over which the reporting person's spouse is co-trustee.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionCommon Stock 44,444 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 2

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 44,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held by the Phillip A. Sharp Irrevocable Trust 11/04/08 FBO Sarah Brokaw, over which the reporting person's spouse is co-trustee.

Read SEC document
October 16, 2019 Filed Oct 18, 2019 23:53 UTC Vir Biotechnology, Inc. VIR · Entity 4522 ConversionCommon Stock 88,888 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-053663 · doc4.xml · nonDerivative · entry 1

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

Read SEC document
October 10, 2019 Filed Oct 11, 2019 23:43 UTC Vir Biotechnology, Inc. VIR · Entity 4522 GrantStock Option (Right to Buy) · Derivative 22,222 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0001209191-19-053067 · doc4.xml · derivative · entry 1

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,222

Underlying: Common Stock · 22,222 shares

Expires 2029-10-10

F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on October 10, 2020, and the remainder vest in 24 equal monthly installments thereafter.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 20:07 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 9,000 $0.00 Strike: $72.01 $0.00
Disclosure

SEC source: 0001735276-19-000067 · edgardoc.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2029-06-30

Read SEC document
June 11, 2019 Filed Jun 12, 2019 16:16 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $5.60 $0.00
Disclosure

SEC source: 0001209191-19-036365 · doc4.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
April 15, 2019 Filed Apr 17, 2019 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $22.09 $0.00
Disclosure

SEC source: 0001735276-19-000037 · edgardoc.xml · derivative · entry 7

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2019-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.

Read SEC document
April 15, 2019 Filed Apr 17, 2019 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 600 $91.40 $54,840.00
Disclosure

SEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 5

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,633

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.

F5 · price: Sale prices ranged from $91.00 to $91.86.

Read SEC document
April 15, 2019 Filed Apr 17, 2019 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 400 $89.97 $35,988.00
Disclosure

SEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 4

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,233

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.

F4 · price: Sale prices ranged from $89.56 to $90.13.

Read SEC document
April 15, 2019 Filed Apr 17, 2019 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 2,200 $89.03 $195,866.00
Disclosure

SEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 3

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,633

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.

F3 · price: Sale prices ranged from $88.49 to $89.43.

Read SEC document
April 15, 2019 Filed Apr 17, 2019 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 11,800 $87.86 $1,036,748.00
Disclosure

SEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,833

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.

F2 · price: Sale prices ranged from $87.48 to $88.43.

Read SEC document
April 15, 2019 Filed Apr 17, 2019 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $22.09 $331,350.00
Disclosure

SEC source: 0001735276-19-000037 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,633

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.

Read SEC document
June 20, 2018 Filed Jun 22, 2018 20:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 9,000 $0.00 Strike: $105.26 $0.00
Disclosure

SEC source: 0001735276-18-000034 · edgardoc.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2028-06-19

Read SEC document
June 14, 2018 Filed Jun 15, 2018 16:29 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $12.95 $0.00
Disclosure

SEC source: 0001179110-18-008623 · edgar.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:39 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $21.35 $0.00
Disclosure

SEC source: 0001553878-18-000021 · edgardoc.xml · derivative · entry 4

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2018-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017.

Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:39 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 15,000 $149.00 $2,235,000.00
Disclosure

SEC source: 0001553878-18-000021 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,795

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017.

Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:39 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $21.35 $320,250.00
Disclosure

SEC source: 0001553878-18-000021 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017.

Read SEC document
March 09, 2018 Filed Mar 13, 2018 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $27.28 $0.00
Disclosure

SEC source: 0001325812-18-000020 · edgardoc.xml · derivative · entry 4

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2018-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017.

Read SEC document
March 09, 2018 Filed Mar 13, 2018 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 15,000 $129.00 $1,935,000.00
Disclosure

SEC source: 0001325812-18-000020 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,795

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017.

Read SEC document
March 09, 2018 Filed Mar 13, 2018 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $27.28 $409,200.00
Disclosure

SEC source: 0001325812-18-000020 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2017.

Read SEC document
June 08, 2017 Filed Jun 12, 2017 16:02 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $14.26 $0.00
Disclosure

SEC source: 0001179110-17-008895 · edgar.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2027-06-07

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
June 08, 2017 Filed Sep 22, 2017 17:20 UTC Amendment Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $14.62 $0.00
Disclosure

SEC source: 0001179110-17-012631 · edgar.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2027-06-07

F2 · derivative.exercise_price: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person.

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
June 02, 2017 Filed Jun 6, 2017 21:02 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 11,250 $0.00 Strike: $71.99 $0.00
Disclosure

SEC source: 0001553878-17-000033 · edgardoc.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2027-06-01

Read SEC document
February 01, 2017 Filed Feb 3, 2017 21:32 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $31.29 $0.00
Disclosure

SEC source: 0001553878-17-000009 · edgardoc.xml · derivative · entry 5

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2017-12-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

Read SEC document
February 01, 2017 Filed Feb 3, 2017 21:32 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 4,829 $40.16 $193,932.64
Disclosure

SEC source: 0001553878-17-000009 · edgardoc.xml · nonDerivative · entry 3

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,795

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

F3 · price: Sale prices ranged from $40.10 to $40.24

Read SEC document
February 01, 2017 Filed Feb 3, 2017 21:32 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 20,171 $39.72 $801,192.12
Disclosure

SEC source: 0001553878-17-000009 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,624

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

F2 · price: Sale prices ranged from $39.09 to $40.08

Read SEC document
February 01, 2017 Filed Feb 3, 2017 21:32 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 25,000 $31.29 $782,250.00
Disclosure

SEC source: 0001553878-17-000009 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

Read SEC document
January 25, 2017 Filed Jan 27, 2017 21:10 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $31.39 $0.00
Disclosure

SEC source: 0001553878-17-000007 · edgardoc.xml · derivative · entry 4

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2017-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

Read SEC document
January 25, 2017 Filed Jan 27, 2017 21:10 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 15,000 $37.95 $569,250.00
Disclosure

SEC source: 0001553878-17-000007 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,795

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

F2 · price: Sale prices ranged from $37.31 to $38.25

Read SEC document
January 25, 2017 Filed Jan 27, 2017 21:10 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $31.39 $470,850.00
Disclosure

SEC source: 0001553878-17-000007 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:12 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $15.91 $0.00
Disclosure

SEC source: 0001553878-17-000004 · edgardoc.xml · derivative · entry 5

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2017-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:12 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 6,200 $38.20 $236,840.00
Disclosure

SEC source: 0001553878-17-000004 · edgardoc.xml · nonDerivative · entry 3

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,795

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

F3 · price: Sale prices ranged from $38.09 to $38.50

Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:12 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 8,800 $37.57 $330,616.00
Disclosure

SEC source: 0001553878-17-000004 · edgardoc.xml · nonDerivative · entry 2

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,995

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

F2 · price: Sale prices ranged from $37.07 to $38.06

Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:12 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 15,000 $15.91 $238,650.00
Disclosure

SEC source: 0001553878-17-000004 · edgardoc.xml · nonDerivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2016.

Read SEC document
September 15, 2016 Filed Sep 19, 2016 06:56 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 22,000 $0.00 Strike: $12.59 $0.00
Disclosure

SEC source: 0001104659-16-145304 · a4.xml · derivative · entry 1

SHARP PHILIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2026-09-14

F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Dr. Sharp's continued service as a director through each applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.